Click here for more information about laboratory operations and procedures
Bullous pemphigoid Antibodies (New test)
|Container type||Red top|
|Amount to Collect||2 mL blood|
|Preferred volume||1 mL serum|
|Min. Volume||0.5 mL serum|
|UCSF Rejection Criteria||Collected in Gold top. Gross hemolysis, lipemia or icterus|
|Processing notes||Spin and freeze aliquot at -20 C. Ship to China basin.|
|Ref Lab Rejection Criteria||Gross hemolysis, lipemia or icterus|
|Normal range||< 9.0 U|
|Synonyms||BP180 AB; BP180 Antibody; BP230 AB; BP230 Antibody; BPAG1 AB; BPAG1 Antibody;BPAG2 AB; BPAG2 Antibody|
|Stability||Room temperature 1.5 days, refrigerated 1 week, frozen 2 weeks|
|Turn around times||5-7 days|
|Additional information||Bullous pemphigoid (BP) is chronic pruritic blistering disorder found mainly in aged persons, characterized by the development of tense blisters over an erythematous or urticarial base. IgG antibasement membrane zone antibodies are found in the serum of patients, and linear IgG and C3 sediment is found on the basement membrane zone of the lesion. Several well characterized variants exist including localized, mucous membrane predominant and pemphigoid gestationis, also referred to as herpes gestationis.
Target antigens of the autoantibodies in BP patient serum are BP230 and BP180 also called BPAG1 and BPAG2. Molecular weight of these antigens is 230 kD and 180 kD, respectively. BP180 is thought to be the direct target of the autoantibody because of its location along the basement membranes, and the autoantibody against BP230 is thought to be secondarily produced.
Antibodies to bullous pemphigoid (BP) BP180 and BP230 have been shown to be present in most patients with pemphigoid. Adequate sensitivities and specificity for disease are documented and Mayo's experience demonstrates a very good correlation between BP180 and BP230 results and the presence of pemphigoid (see "Supportive Data"). However, in those patients strongly suspected to have pemphigoid, either by clinical findings or by routine biopsy, and in whom the BP180/BP230 assay is negative, follow-up testing by #8052 "Cutaneous Immunofluorescence Antibodies (IgG), Serum" is recommended.
Antibody titer correlates with disease activity in many patients. Patients with severe disease can usually be expected to have high titers of antibodies to BP. Titers are expected to decrease with clinical improvement.
|CPT coding||83516-90 x2|
|Last Updated||9/9/2012 1:25:39 PM|
If you have additional questions regarding this test, please call: 415-353-1667